Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year

Rezolute Reports First Quarter

Fiscal 2023 Results and Highlights Company Progress

Phase 2 proof-of-concept study of

RZ402 expected to be initiated by the end of this year

CITY, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to

developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced

its financial results for the first quarter of fiscal 2023 ended September 30, 2022.

am extremely pleased with our progress this year, having reported positive data from both our clinical programs, Phase 1b study of

RZ402 for Diabetic Macular Edema and Phase 2b study of RZ358 for Congenital Hyperinsulinism (HI), as well as completing a $130 million

financing to advance both the molecules into the next phase of clinical studies," said Nevan Charles Elam, Chief Executive

Officer and Founder of Rezolute. "We are on track to initiate a Phase 2 proof-of-concept study for RZ402 by the end of this

year, and we are aligning with regulatory authorities in the U.S. and in Europe on next steps in our Phase 3 clinical program for

and Clinical Highlights

First Quarter Fiscal 2023 Financial

Rezolute strives to disrupt current

treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its novel therapies hold

the potential to both significantly improve outcomes and reduce the treatment burden for patients, the treating physician, and the healthcare

system. Patient, clinician, and advocate voices are integrated in the Company's drug development process, enabling Rezolute to

boldly address a range of severe conditions. Rezolute is steadfast in its mission to create profound, positive, and lasting impact on

patients' lives. The Company's lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism,

a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment

This release, like many written and oral communications presented by Rezolute and

our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the

meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking

statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation

Reform Act of 1995 and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are

based on certain assumptions and describe future plans, strategies, and expectations of Rezolute, are generally identified by use of

words such as "anticipate," "believe," "estimate," "expect," "intend," "plan,"

"project," "seek," "strive," "try," or future or conditional verbs such as "could,"

"may," "should," "will," "would," or similar expressions. Our ability to predict results or the

actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated

results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this

release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements

to reflect events or circumstances that occur after the date on which such statements were made. Important factors that may cause such

a difference include any other factors discussed in Rezolute's filings with the SEC, including the Risk Factors contained in the

Rezolute's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at the SEC's website at www.sec.gov.

You are urged to consider these factors carefully in evaluating the forward-looking statements in this release and are cautioned not

to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement.

Director, Corporate Strategy

Minarovich/Carrie McKim

Canale Communications, Inc.

Condensed Consolidated Financial Statements Data

(in thousands, except per share data)